HERZLIYA, Israel and CALGARY, Alberta, Oct. 23, 2023 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the company's latest groundbreaking findings. Research over the past several months has identified animals that metabolize cannabidiol (CBD), administered as a liposomal CBD injection, in a manner similar to humans. This means that results related to LPT-CBD metabolism obtained from experiments with these types of animals are likely to be very applicable to humans. The Company expects that this development could improve the strength of its application to the FDA for new drug approval.
A Milestone in Drug Approval Process
This groundbreaking discovery, is not unique to our LPT-CBD and can be implemented on these animals using other Cannabidiol (CBD) delivery methods", said Iris Bincovich, CEO of Innocan Pharma. This is an important piece of the puzzle, which expected to not only facilitate our application for FDA approval, but also open new horizons for global medical research with CBD,". "We are committed to using this knowledge to offer innovative health solutions for humans and animals that could go beyond currently known applications."
Transformative Impact on Animal Health
After each injection, various animal species experienced pain relief for several weeks following the injection. This practical application of our liposomal CBD formulation highlights its potential to revolutionize healthcare for animals as well as humans.
A Key Step Towards Regulatory Approval
Understanding the pharmacodynamic (PD), pharmacokinetics (PK) and safety of a drug is paramount for FDA approval. Typically, such studies are first conducted in animals before progressing to human trials and require the animal to show a similar drug metabolic behavior to that of humans. Our groundbreaking data identified animals that have the potential for studying pharmacokinetics, pharmacodynamics, and safety of liposomal-CBD formulation.
About Innocan
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients' quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. (ii) CLX CBD-loaded exosomes platform that may hold the potential to provide a highly synergistic effect of regenerating and anti- inflammatory properties targeting the Central Nervous System (CNS). In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/
For further information, please contact:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the anticipated likelihood of and timing for approval of such applications with the FDA and other regulatory authorities, the potential for new areas of global medical research with CBD, achievement of future regulatory milestones, and the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Logo - https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-reports-a-groundbreaking-discovery-regarding-its-lpd-platform-and-global-cbd-research-301964826.html
Voltar noticias em Inglês